Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

Angela M Carneiro,1,2 Luis S Mendon&ccedil;a,1 Manuel S Falc&atilde;o,1,2 Sofia L Fonseca,1 Elisete M Brand&atilde;o,1 Fernando M Falc&atilde;o-Reis1,21Department of Ophthalmology of Hospital de S&atilde;o Jo&atilde;o, Porto, Portugal; 2Faculty of Medi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carneiro AM, Mendon&ccedil;a LS, Falc&atilde;o MS, Fonseca SL, Brand&atilde;o EM, Falc&atilde;o-Reis FM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/10b2e9f496f242bb83a39b14e6934179
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10b2e9f496f242bb83a39b14e6934179
record_format	dspace
spelling	oai:doaj.org-article:10b2e9f496f242bb83a39b14e69341792021-12-02T07:01:25ZComparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting1177-54671177-5483https://doaj.org/article/10b2e9f496f242bb83a39b14e69341792012-07-01T00:00:00Zhttp://www.dovepress.com/comparative-study-of-1prn-ranibizumab-versus-bevacizumab-in-the-clinic-a10454https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Angela M Carneiro,1,2 Luis S Mendon&ccedil;a,1 Manuel S Falc&atilde;o,1,2 Sofia L Fonseca,1 Elisete M Brand&atilde;o,1 Fernando M Falc&atilde;o-Reis1,21Department of Ophthalmology of Hospital de S&atilde;o Jo&atilde;o, Porto, Portugal; 2Faculty of Medicine of University of Porto, Porto, PortugalPurpose: We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.Methods: A total of 186 wet age-related macular degeneration eyes of 186 treatment-na&iuml;ve patients were compared retrospectively (67 eyes treated with ranibizumab with 91 treated with bevacizumab). At baseline, mean age, best corrected visual acuity, and angiographic lesion types were similar in both groups. Best corrected visual acuity and ocular coherence tomography were evaluated.Results: Sixty eyes treated with ranibizumab and 85 eyes treated with bevacizumab completed a 12-month evaluation. At 12 months, mean best corrected visual acuity increased by +6.65 letters with ranibizumab treatment and by +5.59 with bevacizumab treatment (P = 0.64). Visual acuity improved by &ge;15 letters in 15 eyes treated with ranibizumab and in 21 eyes treated with bevacizumab (P = 0.75). An overall reduction in ocular coherence tomography central thickness occurred for all time points. The mean number of injections per eye was 5.97 with ranibizumab and 5.92 with bevacizumab (P = 0.90).Conclusion: Intravitreal therapies with ranibizumab or bevacizumab have similar visual and anatomical results. These results confirm those of comparison of Age-Related Macular Degeneration Treatment Trials in as-needed cohorts in clinical practice. Randomized long-term clinical trials are necessary to examine the systemic safety of these treatments.Keywords: AMD, anti-VEGF therapy, bevacizumab, choroidal neovascularization, ranibizumab, wet AMD&nbsp;Carneiro AMMendon&ccedil;a LSFalc&atilde;o MSFonseca SLBrand&atilde;o EMFalc&atilde;o-Reis FMDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1149-1157 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Carneiro AM Mendon&ccedil;a LS Falc&atilde;o MS Fonseca SL Brand&atilde;o EM Falc&atilde;o-Reis FM Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
description	Angela M Carneiro,1,2 Luis S Mendon&ccedil;a,1 Manuel S Falc&atilde;o,1,2 Sofia L Fonseca,1 Elisete M Brand&atilde;o,1 Fernando M Falc&atilde;o-Reis1,21Department of Ophthalmology of Hospital de S&atilde;o Jo&atilde;o, Porto, Portugal; 2Faculty of Medicine of University of Porto, Porto, PortugalPurpose: We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.Methods: A total of 186 wet age-related macular degeneration eyes of 186 treatment-na&iuml;ve patients were compared retrospectively (67 eyes treated with ranibizumab with 91 treated with bevacizumab). At baseline, mean age, best corrected visual acuity, and angiographic lesion types were similar in both groups. Best corrected visual acuity and ocular coherence tomography were evaluated.Results: Sixty eyes treated with ranibizumab and 85 eyes treated with bevacizumab completed a 12-month evaluation. At 12 months, mean best corrected visual acuity increased by +6.65 letters with ranibizumab treatment and by +5.59 with bevacizumab treatment (P = 0.64). Visual acuity improved by &ge;15 letters in 15 eyes treated with ranibizumab and in 21 eyes treated with bevacizumab (P = 0.75). An overall reduction in ocular coherence tomography central thickness occurred for all time points. The mean number of injections per eye was 5.97 with ranibizumab and 5.92 with bevacizumab (P = 0.90).Conclusion: Intravitreal therapies with ranibizumab or bevacizumab have similar visual and anatomical results. These results confirm those of comparison of Age-Related Macular Degeneration Treatment Trials in as-needed cohorts in clinical practice. Randomized long-term clinical trials are necessary to examine the systemic safety of these treatments.Keywords: AMD, anti-VEGF therapy, bevacizumab, choroidal neovascularization, ranibizumab, wet AMD&nbsp;
format	article
author	Carneiro AM Mendon&ccedil;a LS Falc&atilde;o MS Fonseca SL Brand&atilde;o EM Falc&atilde;o-Reis FM
author_facet	Carneiro AM Mendon&ccedil;a LS Falc&atilde;o MS Fonseca SL Brand&atilde;o EM Falc&atilde;o-Reis FM
author_sort	Carneiro AM
title	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
title_short	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
title_full	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
title_fullStr	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
title_full_unstemmed	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
title_sort	comparative study of 1+prn ranibizumab versus bevacizumab in the clinical setting
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/10b2e9f496f242bb83a39b14e6934179
work_keys_str_mv	AT carneiroam comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting AT mendonampccedilals comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting AT falcampatildeoms comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting AT fonsecasl comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting AT brandampatildeoem comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting AT falcampatildeoreisfm comparativestudyof1prnranibizumabversusbevacizumabintheclinicalsetting
_version_	1718399616609681408

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

Ejemplares similares